ARTICLE | Product Development
GSK’s early oligo data in HBV point toward potential improvement in functional cure rates
Interim readout shows about 30% of patients had undetectable HBsAg, HBV DNA
June 27, 2022 10:50 PM UTC
GSK is hoping early data from a Phase IIb trial of bepirovirsen could translate into a possible functional cure for at least a subset of chronic HBV patients.
On Saturday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) presented interim data from the B-Clear study of bepirovirsen that showed nearly 30% of patients could be headed for a functional cure. In 227 patients on nucleoside analogues (NA), once-weekly 300 mg bepirovirsen resulted in 28% with both HBsAg and HBV DNA below the lower limit of quantification after 24 weeks. In the non-NA group, 29% of 230 patients showed undetectable HBsAg and HBV DNA over the same time frame...